Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

(2022) Jonathan I. Silverberg et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Long-term 2-Year Safety and Efficacy of Tralokinumab in Adults with Moderate-to-severe Atopic Dermatitis: Interim Analysis of the ECZTEND Open-label Extension Trial

(2022) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

(2022) Kristian Reich et al.   LANCET

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials

(2022) Eric L. Simpson et al.   BRITISH JOURNAL OF DERMATOLOGY

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

(2022) A. Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Atopic Dermatitis

(2021) Sonja Ständer   NEW ENGLAND JOURNAL OF MEDICINE

25854 Effects on type 2 immunity when specifically targeting the interleukin-13 cytokine with tralokinumab

(2021) Emma Guttman-Yassky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

(2021) Andrew Blauvelt et al.   JAMA Dermatology

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial

(2020) J.I. Silverberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

(2020) A. Wollenberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Therapeutic targeting of the IL-13 pathway in skin inflammation

(2020) Carla Tubau et al.   Expert Review of Clinical Immunology

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children

(2020) A. Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis

(2019) Lam C. Tsoi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

(2019) Thomas Bieber   ALLERGY

The IL ‐13– OVOL 1– FLG axis in atopic dermatitis

(2019) Kazuhisa Furue et al.   IMMUNOLOGY

Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study

(2018) J.I. Silverberg et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2

(2017) B. Popovic et al.   JOURNAL OF MOLECULAR BIOLOGY

End points in dermatologic clinical trials: A review for clinicians

(2016) Erin X. Wei et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards

(2016) Masaki Futamura et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin

(2015) K. Szegedi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY